HOME >> MEDICINE >> NEWS
Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection

(May 25, 2004) Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized study was designed to evaluate the safety, tolerability and pharmacokinetics of CZEN-002 in patients with VVC.

The majority of subjects in the study reported evidence of efficacy as determined by potassium hydroxide (KOH) tests and mycological cultures - 88.2 percent and 87.5 percent, respectively. A total of 20 female patients with VVC were enrolled and treated in the trial, and 17 completed the study. KOH testing and mycological cultures indicated that CZEN-002 is active and that five days of treatment provided positive evidence of anti-infective efficacy. CZEN-002 appeared safe and well-tolerated with no severe adverse reactions. In 100 percent of the plasma samples evaluated, concentrations of CZEN 002 were either not detected or were below the limit of quantitation.

"This trial clearly established the efficacy of CZEN-002," said William Smith, M.D., F.A.C.C., lead study investigator and associate professor, clinical medicine, at Tulane University School of Medicine and Louisiana State University Medical Center. "The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year with VVC."

The primary objective of the study was to evaluate the safety and tolerability of vaginally administered CZEN-002. A secondary objective was to assess the systemic absorption of CZEN-002 as determined by the plasma concentrations of the molecule through 21 days following dosing. The CZEN 002 was delivered to the 20 patients in a vaginal gel specifically designed for the purpose of the study.

"This clinical trial marks a major milestone for Zengen," said James M. Lipton, Ph.D., chief scientific officer of Zengen. "Our peptide appears to
'"/>

Contact: Cattaliya Snider
sniderc@ruderfinn.com
310-479-9929
Zengen
25-May-2004


Page: 1 2 3

Related medicine news :

1. Zengens new study reviews novel approach to control inflammation using melanocortin receptors
2. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
3. Study reports women dont experience undue pain, anxiety during mammography screening
4. Risks from labor after prior cesarean delivery low, study reports
5. Federal forum reports Americans aging well, but gaps remain
6. Early reports of thrombosis after insertion of drug-eluting stents
7. Study reports genetic susceptibility to alcoholism in NMDA receptor
8. Parents can provide accurate reports of their childrens ADHD symptoms
9. UCI Tobacco research center reports why teens are most vulnerable to smoking addiction
10. MIT reports new insights in visual recognition
11. Study reports improved method to identify fetal DNA in maternal blood samples

Post Your Comments:
(Date:5/23/2015)... On May 16, the team at Farrell’s eXtreme Bodyshaping ... obstacle run that raised funds for multiple sclerosis. , ... reason we participated was to support people living with MS ... Bodyshaping. “One-hundred percent of the funds raised go to benefit ... only attended by eXtreme Bodyshaping staff, but members of the ...
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ... as simple as dragging and dropping footage into the FCPX ... effect. , Including over 80 stunning flares, ProFlare 5K ... this the ultimate bundle for adding prismatic refractions to any ... are movie files designed for Final Cut Pro X, but ...
(Date:5/22/2015)... 2015 The American College of Traditional ... June. They will hold a webinar on the updates ... class on Classical Chinese Medicine. , Webinar – First ... Given, the Dean of Clinical Education, will lead this ... Professional Doctorate program. ACTCM is currently developing this degree ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... May 22, 2015 “It’s like ... SLP, RAC-CT, CHHRP-QT, Vice President of Clinical Operations/Education ... important ‘language’ that impacts how care is coded ... in long term care reimbursement, operations and compliance ... and talent management, launches a new series of ...
Breaking Medicine News(10 mins):Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
(Date:5/21/2015)... , May 21, 2015 ... ) has announced the addition of the ... Type (Ankle Replacement, Digit Replacement, Elbow Replacement, ... Forecast to 2019" report to their ... for knee replacement was valued at $4,470.9 ...
(Date:5/21/2015)... Research and Markets ( ... "North American Active Wound Care Market by ... & Ulcer), by End-User (In-Patient, & Out-Paient) - ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North ... grow at a CAGR of 3.1% from 2014 ...
(Date:5/21/2015)... May 21, 2015 ... announced the addition of the "Arthroscopy ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose ... size the world market for Arthroscopy Devices. ... trends impacting the market for these products. ...
Breaking Medicine Technology:North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3
Cached News: